Key Highlights:
- Microbot Medical (MBOT, Financial) joins the Russell Microcap® Index, signaling promising growth indicators.
- The company is advancing with FDA discussions regarding its innovative LIBERTY surgical system.
- Analysts suggest significant upside potential with a target price increase of over 250% from the current level.
Microbot Medical (MBOT) has been officially included in the prestigious Russell Microcap® Index, marking a significant milestone for the company as U.S. markets open today. This achievement underscores the company's positive trajectory and is further enhanced by its strategic interactions with the FDA concerning its cutting-edge LIBERTY surgical system.
Wall Street Analysts Forecast
Wall Street analysts have projected a one-year price target for Microbot Medical Inc (MBOT, Financial) at an average of $9.00. This forecast represents a consensus from one analyst, with both the high and low estimates also set at $9.00. This target suggests a potential price increase of 252.94% from the current share price of $2.55. Investors can explore more detailed forecast information by visiting the Microbot Medical Inc (MBOT) Forecast page.
The average brokerage recommendation for Microbot Medical Inc (MBOT, Financial) is currently rated at 2.0, indicating an "Outperform" status based on consensus from one brokerage firm. This recommendation is derived from a rating scale where 1 signifies Strong Buy and 5 denotes Sell, reflecting the brokerage's positive outlook on the company's future performance.
